Learning Impairments Among Survivors of Childhood Cancer: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Learning Impairments Among Survivors of Childhood Cancer (NCT00576472), a registered phase 4 study. The primary outcome is Brain White Matter Volume for Patients Versus Sibling Controls.

2. Clinical Question

3. Trial Design

The registry identifies this study as Phase 4, quadruple-masked, and using a crossover model. It lists St. Jude Children's Research Hospital as sponsor and describes the study as completed. The recorded study start is 2000-01 and the primary completion date is 2010-03. Overall enrollment is listed as 469. Separately, the primary-outcome description says that 505 patients were enrolled for the MRI assessment. Those two enrollment figures differ in the registry record; the reason for the difference is not reported.

The study addresses more than one research question. Its primary outcome compares MRI white matter volume in patients with that of sibling controls. The study description also proposes investigating brain changes that could underlie learning problems and examining methylphenidate in relation to attention and social skills. These aims should not be conflated: the stated primary outcome is an MRI comparison, while the medication-related measures appear among the secondary outcomes.

The registry lists a crossover model, but gives no detailed treatment sequence, allocation method, washout period, or timing of medication periods in the registry record for this analysis. A three-week home crossover phase is named for a secondary parent-rating measure; that does not establish the full crossover procedure. Masking is recorded as quadruple, but the record does not identify which participant or study roles were masked.

The record does not state allocation for the medication comparison and explicitly cautions that this is not a randomized comparison and that the arms are not a like-for-like control comparison. Thus the design labels alone do not establish that treatment groups were exchangeable. Details of recruitment, eligibility, the complete analysis populations, and a protocol-level statistical plan are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Of 505 patients enrolled on the study, 36 were never assessed, and 469 participated in the initial screening. Of the 469 screened patients, 259 did not qualify for further medication phases, 75 qualified but refused to participate and 1 did not show for a scheduled appointment, leaving 134 patients to participate in the two-day MPH In-Lab Phase.

Only the first 6 of 15 groups are shown.

Initial Screening

MPH In-Lab Phase

Reasons for not completing this period:

MPH Cross Over Phase

Reasons for not completing this period:

MPH Home Maintenance Phase

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Of the 505 patients enrolled, 106 did not have MRI acquired to measure brain volume, 16 were not evaluable: 6 had metal artifacts, 3 had motion artifacts, 1 had an acquisition error in MRI image, 4 had tumor on exam, and 2 had ischemic insults. 383 patients had evaluable MRI images. 67 of the 91 sibling controls had evaluable MRI images.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Only the first 6 of 16 groups are shown.

6. Primary Endpoint

The registry lists the primary outcome as Brain White Matter Volume for Patients Versus Sibling Controls, measured over Enrollment to evaluation of MRI, on average 12.8 months..

The primary endpoint is brain white matter volume measured with MRI, expressed as a percentage. The registry describes the summary as a mean, with a 95% confidence interval as the dispersion measure. The intended comparison is between patients and sibling controls, using MRI results captured from -1.8 to 42.36 months from study enrollment. The stated timeframe is enrollment to MRI evaluation, on average 12.8 months. Existing MRI scans close to enrollment could be included.

As general context, a structural MRI measure can describe an anatomical feature rather than a participant’s performance on a learning or attention task. The study description proposes that differences in brain structure could help identify changes underlying learning problems, but the primary endpoint itself is not a direct measure of academic achievement, attention, memory, or social skills. Such functional areas appear in the study rationale and secondary outcomes, not in the title of the primary endpoint.

The endpoint is useful for addressing the stated structural comparison because it gives a quantitative MRI measure that can be summarized across participants. The registry record does not report the patient or sibling mean, the estimated difference, or the confidence interval. Consequently, the magnitude, direction, and precision of the primary comparison cannot be interpreted from these registry entries.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

General statistical context: a mean summarizes the average value of a continuous measurement across participants. For an outcome such as MRI white matter volume, a mean offers a group-level description, but it does not show how values are distributed among individuals. The registry specifies a mean for the primary endpoint. It does not report the group means or the estimated comparison in the registry record, so no numerical interpretation of the average can be made.

The stated dispersion measure is a 95% confidence interval. General interpretation: a confidence interval expresses the uncertainty around an estimated quantity under the statistical method used. A narrower interval indicates greater precision than a wider interval, while the interval’s location indicates which values are compatible with the estimate and method. It is not a guarantee that a particular interval contains the true value. Here, the interval itself is not reported in the registry record available for this analysis, so its width and implications cannot be described.

The primary outcome is a comparison of patients with sibling controls. General context: a between-group comparison can be summarized by a difference in means, with uncertainty around that difference. Interpreting such a comparison requires knowing the estimate, its uncertainty, and how participants entered the groups. The record says the arms are not a like-for-like control comparison and does not state allocation for the intervention comparison. It therefore does not support treating the groups as randomized or assuming that their observed differences are attributable to a treatment.

What does the crossover label establish?

The registry records a crossover model and quadruple masking. In general, a crossover design exposes participants to more than one intervention condition in a sequence, allowing within-participant comparisons when the protocol and analysis support them. Its interpretation depends on details such as sequence assignment, timing, washout, and possible carryover. Those details are not reported in the registry record. The three-week home crossover phase is specified for a secondary parent-rating measure, but it does not provide the missing details for the complete design. The masking label also does not identify which roles were masked.

How should the MRI timing be understood?

The registry says MRI results were captured between -1.8 and 42.36 months from enrollment, and gives an average interval of 12.8 months from enrollment to MRI evaluation. It also allows existing MRI scans very close to enrollment. This timing information describes when eligible imaging could have been obtained; it does not establish that all scans were collected at the same interval or that timing was adjusted for in the analysis. Whether timing varied between groups, and how that variation was handled, is not reported in the registry record.

What does over-dispersion mean in general?

General context: over-dispersion occurs when observed variability is greater than a model assumes. It is especially relevant for some count outcomes and can make conventional uncertainty estimates too small if ignored. The primary outcome is described as a continuous mean, not a count outcome. The registry entries do not report a model specification, a variance assessment, or an over-dispersion adjustment. It would therefore be inappropriate to claim that such an adjustment was used or needed for this analysis.

What can planning calculations say?

The registry’s sample-size assumptions describe a planning illustration based on the observed effect, using a two-sided significance level of 0.05, equal allocation, and a normal approximation. The target effect is described as a stated fraction of the observed effect. The listed illustration is not the trial’s own design justification and should not be read as observed power. The registry entries available for this analysis do not include the actual planning rows or numerical participant requirements, and they do not report the trial’s own sample-size justification. A retrospective illustration based on an observed effect cannot replace a prospective design calculation or establish that a study was adequately powered.

The record does not report an interim-analysis plan, a prespecified analysis model, covariate adjustment, or a detailed statistical analysis plan. Without these details and without the endpoint estimates, it is not possible to assess the analysis choices or reproduce the sponsor’s primary result from the registry entries. Any recalculated summaries would require posted summary statistics, which are not included.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists 34 outcome measures and 58 analyses. Multiple outcomes and analyses create a multiplicity issue: when many statistical tests are conducted, the chance of at least one apparently unusual result can increase if each test is assessed separately. General approaches can include prespecifying a primary analysis, adjusting thresholds or intervals, or treating secondary analyses as exploratory. The registry entries do not report a multiplicity strategy, so it is not possible to determine whether or how the analyses accounted for multiple testing.

Missing MRI measurements are explicitly described. The primary-outcome text says 106 patients did not have MRI acquired to measure brain volume and 16 were not evaluable, with reasons listed for the latter group. It reports 383 patients with evaluable MRI images, but the sibling count is truncated after “67 of the 91 sib”. The full patient and sibling analysis populations, and the method used to handle missing or unusable measurements, are not reported in the registry record available for this analysis.

General context: complete-case analysis uses participants with observed outcome measurements, while other approaches may use modeling or imputation under stated assumptions. The choice matters because conclusions can depend on whether missingness is related to participant characteristics or the unobserved outcome. No specific approach or missingness assumption is reported, so none should be attributed to the study.

The overall enrollment field lists 469, while the primary-outcome description refers to 505 patients enrolled. The registry does not explain the difference. It also does not specify which populations were used for the medication analyses or whether all registered outcomes were analyzed in the same participants. These gaps limit assessment of selection, missing-data handling, and the scope of each analysis.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

The adverse-event figures list Mild, Moderate, and High groups. For each group, the serious-event count is 0 and the other affected count is 0; the corresponding at-risk counts are 230, 40, and 199. These are the reported counts in the registry record and should be read with their listed group denominators rather than as counts for every person enrolled in the study.

The deaths field is null for each group. A null entry is not a reported zero; the death count is not reported in the registry record. The list of top serious terms is empty, which means no terms are listed in that field, not that the record supplies a detailed account of all possible safety observations.

These figures alone do not establish that no adverse events occurred. They describe only the event categories and counts recorded in these fields. The record does not provide additional context about event collection, observation periods, attribution, or whether the displayed groups cover every participant exposed to the drug. The safety counts should therefore be interpreted as registry reporting, not as a comprehensive determination of risk.

12. What the Result Does, and Does Not, Mean

The study’s registered primary question is a structural comparison: MRI-derived white matter volume in patients versus sibling controls. The record gives the measurement unit, summary type, confidence-interval type, and timing information. It also documents that some intended MRI measurements were unavailable or not evaluable. These details help define what the analysis was intended to address, but they do not provide its numerical result.

The primary outcome mean, group comparison, and confidence interval are not reported in the registry record available for this analysis. As a result, there is no basis to state the direction or size of a difference, or how precise an estimate might be. The study description’s hypotheses about brain changes and learning problems are motivations for the research, not evidence that those hypotheses were confirmed.

The listed methylphenidate intervention and secondary measures address related but distinct questions about parent- and teacher-rated attention, behavior, and social skills. The record names a three-week home crossover phase for one parent-rating outcome. It does not include the secondary outcome estimates in the registry record, and it cautions that the arms are not a like-for-like control comparison. The intervention’s effectiveness therefore cannot be judged from these details.

In general, a study design and its measurements determine what kind of question can be answered; neither automatically establishes causation or clinical importance. Interpretation also depends on the analysis population, missing-data handling, estimates, uncertainty, and prespecified methods. Several of these details are not reported in the registry record. The registry entries support describing the study aims and design labels, but not a conclusion about whether methylphenidate changed outcomes or whether patient and sibling MRI measures differed.

Accordingly, the result does not establish that a treatment works or does not work, nor does it quantify the prevalence or severity of learning problems among survivors. Those claims require outcome results and supporting analysis details that are not reported in the registry record available for this analysis.

13. Why This Trial Matters Statistically

This study brings together two statistical questions that are easy to blur: whether MRI white matter volume differs between patients and sibling controls, and whether methylphenidate is associated with changes in learning-related ratings. Keeping those questions separate is important because the primary endpoint is an MRI measure, while attention, behavior, and social skills are represented among secondary outcomes. Evidence for one would not automatically answer the other.

The record also illustrates why analysis populations matter. MRI acquisition and evaluability determine which participants contribute to a structural comparison. The stated counts show that not every enrolled patient had an evaluable MRI, while the sibling description is incomplete. A clear account of who contributed data and how unavailable measurements were handled is essential for judging how representative the analyzed sample may be.

Multiple registered outcomes and analyses raise a further interpretive issue. Without a reported multiplicity strategy, readers cannot tell how the study distinguished a confirmatory finding from a chance result among many analyses. This is particularly important when a study has several parent- and teacher-rated measures alongside an imaging outcome.

Finally, design labels do not replace estimates. A crossover label, masking designation, or registered hypothesis cannot tell readers the magnitude or precision of an effect. The registry record does not report the primary estimate or interval, so the statistical significance and practical importance of the MRI comparison cannot be judged. The central statistical lesson is to separate a well-defined research question from the evidence needed to answer it: outcome estimates, uncertainty, analysis populations, and a transparent analysis plan.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The central limitation for interpreting the primary outcome is that its numerical result is not reported in the registry record available for this analysis. The record identifies a mean and a 95% confidence interval but gives neither group values nor a comparison estimate or interval. Direction, magnitude, and precision therefore remain unknown.

The primary-outcome population description is incomplete. It gives patient MRI acquisition and evaluability counts, but the sibling statement is truncated. The overall enrollment field lists 469, while the primary-outcome description refers to 505 patients enrolled; the reason for the discrepancy is not reported. The registry also does not describe the full analysis population or how missing and unusable scans were handled.

Design information is limited. The registry labels the study crossover and quadruple-masked, but does not report the treatment sequence, allocation process, washout, or masking roles. It cautions that the comparison is not randomized and the arms are not like-for-like controls. These gaps make it difficult to assess the design and potential for confounding in the intervention comparison.

The record lists many outcomes and analyses but does not report a multiplicity procedure, a complete statistical analysis plan, or an interim-analysis plan. It also does not give the trial’s own sample-size justification. The sample-size assumptions describe a planning illustration rather than the trial design; numerical illustration results are not included in the registry record for this analysis.

Finally, the safety fields do not provide deaths counts—the relevant entries are null—and contain no listed serious-event terms. Without broader information on event collection and follow-up, those fields should not be treated as a complete safety assessment.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Learning Impairments Among Survivors of Childhood Cancer — NCT00576472.
• Registry record last updated 2017-05-30; status last verified 2013-02.
• Results first posted 2012-04-16.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes a completed Phase 4 study sponsored by St. Jude Children's Research Hospital, with a crossover model and quadruple masking. It lists overall enrollment as 469, a start date of 2000-01, and primary completion in 2010-03. The conditions include acute lymphoblastic leukemia and brain tumors.

The primary outcome is MRI-measured brain white matter volume, expressed as a percentage and summarized as a mean with a 95% confidence interval, comparing patients with sibling controls. The MRI timing is described as enrollment to evaluation, on average 12.8 months. The registry also lists methylphenidate and multiple secondary attention, behavior, and social-skill measures.

The available record does not report the primary estimate or interval. It documents missing and unevaluable MRI scans, gives an incomplete sibling count, and contains different enrollment figures in the overall and primary-outcome descriptions. These limitations prevent a numerical interpretation of the primary comparison.